BREAKING NEWS: Meta-Analysis Finds Increased Risk of MI with Rosiglitazone (Avandia)

Article

CLEVELAND -- A meta-analysis of 42 randomized trials released online by the New England Journal of Medicine today found a 43% increase in the risk of myocardial infarction among type 2 diabetics treated with rosiglitazone (Avandia), although the absolute number of events was small. A journal editorial says FDA action is warranted, and a congressional inquiry is expected.

CLEVELAND, May 21 -- A meta-analysis of 42 randomized trials released online by the New England Journal of Medicine today found a 43% increase in the risk of myocardial infarction among type 2 diabetics treated with rosiglitazone (Avandia), although the absolute number of events was small. A journal editorial says FDA action is warranted, and a congressional inquiry is expected.

Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity

FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea with Obesity

Patient Care Editorial Staff
December 20th 2024
Article

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Crinecerfont for Congenital Adrenal Hyperplasia Now Commercially Available, Neurocrine Biosciences Announces / image credit courtesy of Neurocrine Biosciences

Crinecerfont for Congenital Adrenal Hyperplasia Now Commercially Available, Neurocrine Biosciences Announces

Grace Halsey
December 20th 2024
Article

The first in class CRF-1 receptor antagonist allows people with CAH to reduce glucocorticoid doses while androgen levels are maintained or improved.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Sydney Jennings
October 25th 2023
Podcast

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Atogepant Improves QoL in Chronic, Episodic Migraine: Daily Dose / image credit: ©New Africa/AdobeStock

Atogepant Improves QoL in Chronic, Episodic Migraine: Daily Dose

Sydney Jennings
December 20th 2024
Article

Your daily dose of the clinical news you may have missed.

Women at higher risk for PTSD than men, according to large twin-sibling study / image credit ©Microgen/stock.adobe.com

Women are at Higher Genetic Risk for PTSD than Men, According to Large Twin-Sibling Study

Grace Halsey
December 19th 2024
Article

In the largest twin-sibling study to date of the inherited biological risk of PTSD, researchers found additive genetic and unique environmental effects contributed to the disorder.

© 2024 MJH Life Sciences

All rights reserved.